Skip to Content
  • Previous Rank9
  • Revenue 3 Yr Annual Growth Rate59%
  • Revenue 3 Yr Growth Rank9
  • EPS 3 Yr Annual Growth Rate112%
  • EPS 3 Yr Growth Rank13
  • Total Return 3 Yr Annual Rate19%
  • Total Return 3 Yr Rank
    66

Revenues from new (and safer) HIV meds, including Descovy, Genvoya, and Odefsey, are soothing a drop-off in this biopharma company’s hepatitis C drug sales.

Fortune Data StoreLooking for leads, investment insights, or competitive intelligence?Get Premium Access

Company Information

Location
Foster City, Calif.
Industry
Pharmaceuticals
Sector
Health Care
Current Streak2
Years on List7
CEO
John Milligan
Websitehttp://www.gilead.com
Revenue and net income for the four quarters ended on or before April 30, 2016.!Total return for the period ended June 30, 2016.

Revenue, Net Income

Revenue Past Four Quarters ($M)$32,839
Net Income Past Four Quarters ($M)$17,341

Growth Rates and Ranks

Revenue 3 Yr Growth Rank9
EPS 3 Yr Annual Growth Rate112%
EPS 3 Yr Growth Rank13
Total Return 3 Yr Annual Rate19%
Total Return 3 Yr Rank
66